Malignant Mesothelioma: Clinical and Imaging Findings

  • Naveed Z. Alam
  • Raja M. FloresEmail author


Malignant mesothelioma is a rare tumor. The incidence has been rising since the 1970s with a male to female ratio of 5:1 which is likely due to the increased frequency of occupational exposure to asbestos in men. The clinical and imaging features of malignant mesothelioma vary widely depending on the stage of presentation. A significantly high index of suspicion is required to make a diagnosis due to the nonspecific nature of the symptoms, signs, and early radiology. Invasive surgical procedures are often required to obtain adequate tumor tissue samples to secure the diagnosis.


Malignant mesothelioma Mesothelioma surgical treatment Mesothelioma imaging Mesothelioma symptoms Mesothelioma clinical findings 


  1. 1.
    Wagner JC, Sleggs CA, Marchand P. Diffuse pleural mesothelioma and asbestos exposure in the North Western Cape Province. Br J Ind Med. 1960;17:260–71.PubMedPubMedCentralGoogle Scholar
  2. 2.
    Verschraegen C. Mesothelioma: incidence and survival rates in the United States. Proc Am Soc Clin Oncol. 2003;22:869.Google Scholar
  3. 3.
    Bégin R. Asbestos related diseases. In: Harber P, Schenker MB, Balmes JR, editors. Occupational and environmental respiratory disease. St. Louis: Mosby-Year Book; 1996. p. 293–321.Google Scholar
  4. 4.
    Sheard JDH, et al. Pneumothorax and malignant mesothelioma in patients over the age of 40. Thorax. 1991;46:584–5.CrossRefGoogle Scholar
  5. 5.
    Law MR, Hodson ME, Heard BE. Malignant mesothelioma of the pleura: relation between histological type and clinical behaviour. Thorax. 1982;37:810–5.CrossRefGoogle Scholar
  6. 6.
    Ruffie P, et al. Diffuse malignant mesothelioma of the pleura in Ontario and Quebec: a retrospective study of 332 patients. J Clin Oncol. 1981;7:1157–68.CrossRefGoogle Scholar
  7. 7.
    Olesen LL, Thorshauge H. Thrombocytosis in patients with malignant pleural mesothelioma. Cancer. 1988;62:1194–6.CrossRefGoogle Scholar
  8. 8.
    Rudd RM. Malignant mesothelioma. Br Med Bull. 2010;93:105–23.CrossRefGoogle Scholar
  9. 9.
    Munkholm-Larsen S, Cao CQ, Yan TD. Malignant peritoneal mesothelioma. World J Gastrointest Surg. 2009;1(1):38–48.CrossRefGoogle Scholar
  10. 10.
    Antman KH. Current concepts: malignant mesothelioma. N Engl J Med. 1980;303:200–2.CrossRefGoogle Scholar
  11. 11.
    Qureshi NR, Gleeson FV. Imaging of pleural disease. Clin Chest Med. 2006;27:193–213.CrossRefGoogle Scholar
  12. 12.
    Gotfried MH, Quan SF, Sobonya RE. Diffuse epithelial pleural mesothelioma presenting as a solitary lung mass. Chest. 1983;84:99.CrossRefGoogle Scholar
  13. 13.
    Ng CS, Munden RF, Libshitz HI. Malignant pleural mesothelioma: the spectrum of manifestations on CT in 70 cases. Clin Radiol. 1999;54:415–21.CrossRefGoogle Scholar
  14. 14.
    Mujoomdar AA, Sugarbaker DJ. Diffuse pleural malignancies. In: Sugarbaker DJ, Bueno R, Krasna MJ, Mentzer SJ, Zellos L, editors. Adult chest surgery. New York: McGraw Hill Medical; 2009. p. 838–48.Google Scholar
  15. 15.
    Heelan RT, Rusch VW, Begg CB, et al. Staging of malignant pleural mesothelioma: comparison of CT and MR imaging. AJR Am J Roentgenol. 1999;172:1039–47.CrossRefGoogle Scholar
  16. 16.
    Bernard F, Sterman D, Smith RJ, et al. Metabolic imaging of malignant pleural mesothelioma with fluorodeoxyglucose positron emission tomography. Chest. 1998;9:713–72.CrossRefGoogle Scholar
  17. 17.
    Flores RM, Akhurst T, Gonen M, et al. Positron emission tomography defines metastatic disease but not locoregional disease in patients with malignant pleural mesothelioma. J Thorac Cardiovasc Surg. 2003;126:11–6.CrossRefGoogle Scholar
  18. 18.
    Flores RM, Akhurst T, Gonen M, et al. Positron emission tomography predicts survival in malignant pleural mesothelioma. J Thorac Cardiovasc Surg. 2006;132:763–8.CrossRefGoogle Scholar
  19. 19.
    Ismail-Khan R, Robinson LA, Williams CC, et al. Malignant pleural mesothelioma: a comprehensive review. Cancer Control. 2006;13:255–63.CrossRefGoogle Scholar
  20. 20.
    Metintas M, Ozdemir N, Isiksoy S, et al. CT-guided pleural needle biopsy in the diagnosis of malignant mesothelioma. J Comput Assist Tomogr. 1995;19:370–4.CrossRefGoogle Scholar
  21. 21.
    Agarwal PP, Seely JM, Matzinger FR, et al. Pleural mesothelioma: sensitivity and incidence of needle track seeding after image-guided biopsy versus surgical biopsy. Radiology. 2006;241:589–94.CrossRefGoogle Scholar
  22. 22.
    Rai AJ, Flores RM, Mathew A, et al. Soluble mesothelin related peptides (SMRP) and osteopontin as protein biomarkers for malignant mesothelioma: analytical validation of ELISA based assays and characterization at mRNA and protein levels. Clin Chem Lab Med. 2010;48(2):271–8.CrossRefGoogle Scholar
  23. 23.
    Robinson BW, Creaney J, Lake R, et al. Mesothelin-family proteins and diagnosis of mesothelioma. Lancet. 2003;362:1612–6.CrossRefGoogle Scholar
  24. 24.
    West SD, Lee GYC. Management of malignant pleural mesothelioma. Clin Chest Med. 2006;27:335–54.CrossRefGoogle Scholar
  25. 25.
    Butchart EG, Ashcroft T, Barnsley WC, et al. Pleuropneumonectomy in the management of diffuse malignant mesothelioma of the pleura: experience with 29 patients. Thorax. 1976;31:15–24.CrossRefGoogle Scholar
  26. 26.
    Edge SB, Byrd DR, Compton CC. AJCC cancer staging manual. 7th ed. New York: Springer; 2010.Google Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  1. 1.Division of Cardiothoracic SurgerySt. Vincent’s HospitalMelbourneAustralia
  2. 2.Department of Thoracic SurgeryIcahn School of Medicine at the Mount Sinai Health SystemNew YorkUSA

Personalised recommendations